ZyVersa Therapeutics, Inc.
ZVSA· OTC
ZVSAZyVersa Therapeutics, Inc.
Filed Aug 21, 2023 · 10-Q · 52 days after period end · 0001493152-23-029603
| Metric | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|
| Net Income | -$78.51M | -$393.64K | -$1.90K |
| EPS Diluted | -$1,694.12 | — | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ZyVersa Therapeutics, Inc. · CIK 1859007 · Engraved from SEC EDGAR
ended Jun 30, 2023 · filed Aug 21, 2023 · 52 d after period end
